Justempa-LN 25/5 Tablet is a combination oral antidiabetic medication containing Empagliflozin 25 mg and Linagliptin 5 mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The synergistic action of these agents improves glycemic control without significant risk of hypoglycemia when used appropriately. Justempa-LN 25/5 is typically prescribed as an adjunct to diet and exercise in adults inadequately controlled on monotherapy or other antidiabetic agents. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment. Common adverse effects may include urinary tract infections, nasopharyngitis, and gastrointestinal disturbances. Regular monitoring of renal function, blood glucose, and signs of volume depletion is recommended during therapy. This combination offers a convenient once-daily dosing regimen, improving patient adherence and overall management of type 2 diabetes mellitus.

Dosage & How to Use